Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
Completed
- Conditions
- Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 246
- Registration Number
- NCT02444845
A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer
Completed
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 211
- Registration Number
- NCT02443467
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Phase 1
Completed
- Conditions
- Malignant Melanoma, Cancer
- Interventions
- Drug: VemurafenibDrug: 14C-Labeled Vemurafenib
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02441465
- Locations
- 🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina
Completed
- Conditions
- Basal Cell Carcinoma
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT02438644
A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)
Phase 1
Completed
- Conditions
- Major Depressive Disorder, Healthy Volunteer
- Interventions
- Drug: BasimglurantDrug: Placebo
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT02433093
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT02431208
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Phase 3
Completed
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 902
- Registration Number
- NCT02425891
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇦Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, Ukraine
🇺🇸The Methodist Cancer Center, Houston, Texas, United States
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
Completed
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02424682
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
Completed
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 624
- Registration Number
- NCT02422069
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Phase 3
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 915
- Registration Number
- NCT02420821
- Locations
- 🇺🇸
Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Florida Cancer Specialists - Port Charlotte, Port Charlotte, Florida, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath